Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis
OBJECTIVE:High-mobility group box 1 (HMGB1) has been proposed as a late mediator of sepsis, but human data are sparse and conflicting. We describe plasma HMGB1 concentrations in humans with community-acquired pneumonia (CAP), the most common cause of severe sepsis, and test the hypotheses that HMGB1...
Gespeichert in:
Veröffentlicht in: | Critical care medicine 2007-04, Vol.35 (4), p.1061-1067 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1067 |
---|---|
container_issue | 4 |
container_start_page | 1061 |
container_title | Critical care medicine |
container_volume | 35 |
creator | Angus, Derek C Yang, LiHong Kong, Lan Kellum, John A Delude, Russell L Tracey, Kevin J Weissfeld, Lisa |
description | OBJECTIVE:High-mobility group box 1 (HMGB1) has been proposed as a late mediator of sepsis, but human data are sparse and conflicting. We describe plasma HMGB1 concentrations in humans with community-acquired pneumonia (CAP), the most common cause of severe sepsis, and test the hypotheses that HMGB1 levels are higher in CAP than healthy controls, higher in CAP with severe sepsis than CAP without severe sepsis, and higher in severe sepsis nonsurvivors than survivors.
DESIGN:Random, outcome-stratified sample from a prospective study of 1,895 subjects hospitalized with CAP.
SETTING:Twenty-eight U.S. teaching and community hospitals.
PATIENTS:There were 122 CAP subjects (43 never developed severe sepsis, 49 developed severe sepsis and survived hospitalization, and 30 developed severe sepsis and died) and 38 healthy controls.
INTERVENTIONS:None.
MEASUREMENTS AND MAIN RESULTS:Median day of onset of severe sepsis was day of admission. HMGB1 was measured daily for the first week and analyzed using repeated-measures models with and without multivariable adjustment for baseline characteristics. HMGB1 concentrations were higher in CAP subjects compared with controls (median concentration on day of admission vs. controls, 190 vs. 0 ng/mL, p = .0001; 93.7% of all CAP measurements were elevated). HMGB1 remained elevated throughout the hospital course with no significant trend (p = .64) and did not differ between those with and without severe sepsis (p = .30). HMGB1 concentrations were higher in severe sepsis nonsurvivors than survivors (p = .001). HMGB1 concentrations remained elevated at discharge (median final HMGB1 measure, 176 ng/mL). Findings persisted in multivariable models and were robust to sensitivity analyses using alternative definitions of severe sepsis.
CONCLUSIONS:HMGB1 is elevated in almost all CAP subjects, and higher circulating HMGB1 is associated with mortality. But immunodetectable HMGB1 levels were also persistently elevated in those patients who fared well. Thus, additional work is needed to understand the biological activities of serum HMGB1 in sepsis. |
doi_str_mv | 10.1097/01.CCM.0000259534.68873.2A |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70363732</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70363732</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4490-6882114a9fb1b7dba25fab9e255209cca791b2b45e95c96871506babd2c553743</originalsourceid><addsrcrecordid>eNpNkd1uEzEQhVcIRNPCKyALCVQuNoz_1jF3IYIWqRU3cG3ZjpMYvPZi7zb0FXhqTBIpWBpZM_rmjGZO07zGMMcgxXvA89Xqfg71ES45ZfNusRB0TpZPmhnmFFogkj5tZgASWsokvWguS_kBgBkX9HlzgQWljLBu1vxZ-WynoEcft2jnt7u2T8YHPz6ibU7TgEz6jTC6vr2_-YjfIZuidXHMlU-xIJ0dcsE96NGtkY8VHndoijb1Q_D2UB2im_oUvUY6_p_tfUWLe3BVorih-PKiebbRobiXp_-q-f7507fVbXv39ebLannXWsbqPnVXgjHTcmOwEWujCd9oIx3hnIC0VguJDTGMO8mt7BYCc-iMNmtiOaeC0avm7VF3yOnX5Mqoel-sC0FHl6aiBNCOCkoq-OEI2pxKyW6jhux7nR8VBvXPCQVYVSfU2Ql1cEKRZW1-dZoymd6tz62n01fgzQnQxeqwyTpaX87coiOYSqgcO3L7FEaXy88w7V1WO6fDuDuMplWuJQACWM3aGhjoX9LRosE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70363732</pqid></control><display><type>article</type><title>Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><creator>Angus, Derek C ; Yang, LiHong ; Kong, Lan ; Kellum, John A ; Delude, Russell L ; Tracey, Kevin J ; Weissfeld, Lisa</creator><creatorcontrib>Angus, Derek C ; Yang, LiHong ; Kong, Lan ; Kellum, John A ; Delude, Russell L ; Tracey, Kevin J ; Weissfeld, Lisa ; GenIMS Investigators</creatorcontrib><description>OBJECTIVE:High-mobility group box 1 (HMGB1) has been proposed as a late mediator of sepsis, but human data are sparse and conflicting. We describe plasma HMGB1 concentrations in humans with community-acquired pneumonia (CAP), the most common cause of severe sepsis, and test the hypotheses that HMGB1 levels are higher in CAP than healthy controls, higher in CAP with severe sepsis than CAP without severe sepsis, and higher in severe sepsis nonsurvivors than survivors.
DESIGN:Random, outcome-stratified sample from a prospective study of 1,895 subjects hospitalized with CAP.
SETTING:Twenty-eight U.S. teaching and community hospitals.
PATIENTS:There were 122 CAP subjects (43 never developed severe sepsis, 49 developed severe sepsis and survived hospitalization, and 30 developed severe sepsis and died) and 38 healthy controls.
INTERVENTIONS:None.
MEASUREMENTS AND MAIN RESULTS:Median day of onset of severe sepsis was day of admission. HMGB1 was measured daily for the first week and analyzed using repeated-measures models with and without multivariable adjustment for baseline characteristics. HMGB1 concentrations were higher in CAP subjects compared with controls (median concentration on day of admission vs. controls, 190 vs. 0 ng/mL, p = .0001; 93.7% of all CAP measurements were elevated). HMGB1 remained elevated throughout the hospital course with no significant trend (p = .64) and did not differ between those with and without severe sepsis (p = .30). HMGB1 concentrations were higher in severe sepsis nonsurvivors than survivors (p = .001). HMGB1 concentrations remained elevated at discharge (median final HMGB1 measure, 176 ng/mL). Findings persisted in multivariable models and were robust to sensitivity analyses using alternative definitions of severe sepsis.
CONCLUSIONS:HMGB1 is elevated in almost all CAP subjects, and higher circulating HMGB1 is associated with mortality. But immunodetectable HMGB1 levels were also persistently elevated in those patients who fared well. Thus, additional work is needed to understand the biological activities of serum HMGB1 in sepsis.</description><identifier>ISSN: 0090-3493</identifier><identifier>EISSN: 1530-0293</identifier><identifier>DOI: 10.1097/01.CCM.0000259534.68873.2A</identifier><identifier>PMID: 17334246</identifier><identifier>CODEN: CCMDC7</identifier><language>eng</language><publisher>Hagerstown, MD: by the Society of Critical Care Medicine and Lippincott Williams & Wilkins</publisher><subject>Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Community-Acquired Infections - blood ; Community-Acquired Infections - complications ; Emergency and intensive care: infection, septic shock ; Female ; HMGB1 Protein - blood ; Humans ; Immunoblotting ; Immunomodulators ; Intensive care medicine ; Intensive Care Units ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Pneumonia - blood ; Pneumonia - complications ; Pneumonia - physiopathology ; Prospective Studies ; Sepsis - blood ; Sepsis - complications ; Sepsis - physiopathology ; Severity of Illness Index</subject><ispartof>Critical care medicine, 2007-04, Vol.35 (4), p.1061-1067</ispartof><rights>2007 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4490-6882114a9fb1b7dba25fab9e255209cca791b2b45e95c96871506babd2c553743</citedby><cites>FETCH-LOGICAL-c4490-6882114a9fb1b7dba25fab9e255209cca791b2b45e95c96871506babd2c553743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18621390$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17334246$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Angus, Derek C</creatorcontrib><creatorcontrib>Yang, LiHong</creatorcontrib><creatorcontrib>Kong, Lan</creatorcontrib><creatorcontrib>Kellum, John A</creatorcontrib><creatorcontrib>Delude, Russell L</creatorcontrib><creatorcontrib>Tracey, Kevin J</creatorcontrib><creatorcontrib>Weissfeld, Lisa</creatorcontrib><creatorcontrib>GenIMS Investigators</creatorcontrib><title>Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis</title><title>Critical care medicine</title><addtitle>Crit Care Med</addtitle><description>OBJECTIVE:High-mobility group box 1 (HMGB1) has been proposed as a late mediator of sepsis, but human data are sparse and conflicting. We describe plasma HMGB1 concentrations in humans with community-acquired pneumonia (CAP), the most common cause of severe sepsis, and test the hypotheses that HMGB1 levels are higher in CAP than healthy controls, higher in CAP with severe sepsis than CAP without severe sepsis, and higher in severe sepsis nonsurvivors than survivors.
DESIGN:Random, outcome-stratified sample from a prospective study of 1,895 subjects hospitalized with CAP.
SETTING:Twenty-eight U.S. teaching and community hospitals.
PATIENTS:There were 122 CAP subjects (43 never developed severe sepsis, 49 developed severe sepsis and survived hospitalization, and 30 developed severe sepsis and died) and 38 healthy controls.
INTERVENTIONS:None.
MEASUREMENTS AND MAIN RESULTS:Median day of onset of severe sepsis was day of admission. HMGB1 was measured daily for the first week and analyzed using repeated-measures models with and without multivariable adjustment for baseline characteristics. HMGB1 concentrations were higher in CAP subjects compared with controls (median concentration on day of admission vs. controls, 190 vs. 0 ng/mL, p = .0001; 93.7% of all CAP measurements were elevated). HMGB1 remained elevated throughout the hospital course with no significant trend (p = .64) and did not differ between those with and without severe sepsis (p = .30). HMGB1 concentrations were higher in severe sepsis nonsurvivors than survivors (p = .001). HMGB1 concentrations remained elevated at discharge (median final HMGB1 measure, 176 ng/mL). Findings persisted in multivariable models and were robust to sensitivity analyses using alternative definitions of severe sepsis.
CONCLUSIONS:HMGB1 is elevated in almost all CAP subjects, and higher circulating HMGB1 is associated with mortality. But immunodetectable HMGB1 levels were also persistently elevated in those patients who fared well. Thus, additional work is needed to understand the biological activities of serum HMGB1 in sepsis.</description><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Community-Acquired Infections - blood</subject><subject>Community-Acquired Infections - complications</subject><subject>Emergency and intensive care: infection, septic shock</subject><subject>Female</subject><subject>HMGB1 Protein - blood</subject><subject>Humans</subject><subject>Immunoblotting</subject><subject>Immunomodulators</subject><subject>Intensive care medicine</subject><subject>Intensive Care Units</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumonia - blood</subject><subject>Pneumonia - complications</subject><subject>Pneumonia - physiopathology</subject><subject>Prospective Studies</subject><subject>Sepsis - blood</subject><subject>Sepsis - complications</subject><subject>Sepsis - physiopathology</subject><subject>Severity of Illness Index</subject><issn>0090-3493</issn><issn>1530-0293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkd1uEzEQhVcIRNPCKyALCVQuNoz_1jF3IYIWqRU3cG3ZjpMYvPZi7zb0FXhqTBIpWBpZM_rmjGZO07zGMMcgxXvA89Xqfg71ES45ZfNusRB0TpZPmhnmFFogkj5tZgASWsokvWguS_kBgBkX9HlzgQWljLBu1vxZ-WynoEcft2jnt7u2T8YHPz6ibU7TgEz6jTC6vr2_-YjfIZuidXHMlU-xIJ0dcsE96NGtkY8VHndoijb1Q_D2UB2im_oUvUY6_p_tfUWLe3BVorih-PKiebbRobiXp_-q-f7507fVbXv39ebLannXWsbqPnVXgjHTcmOwEWujCd9oIx3hnIC0VguJDTGMO8mt7BYCc-iMNmtiOaeC0avm7VF3yOnX5Mqoel-sC0FHl6aiBNCOCkoq-OEI2pxKyW6jhux7nR8VBvXPCQVYVSfU2Ql1cEKRZW1-dZoymd6tz62n01fgzQnQxeqwyTpaX87coiOYSqgcO3L7FEaXy88w7V1WO6fDuDuMplWuJQACWM3aGhjoX9LRosE</recordid><startdate>200704</startdate><enddate>200704</enddate><creator>Angus, Derek C</creator><creator>Yang, LiHong</creator><creator>Kong, Lan</creator><creator>Kellum, John A</creator><creator>Delude, Russell L</creator><creator>Tracey, Kevin J</creator><creator>Weissfeld, Lisa</creator><general>by the Society of Critical Care Medicine and Lippincott Williams & Wilkins</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200704</creationdate><title>Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis</title><author>Angus, Derek C ; Yang, LiHong ; Kong, Lan ; Kellum, John A ; Delude, Russell L ; Tracey, Kevin J ; Weissfeld, Lisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4490-6882114a9fb1b7dba25fab9e255209cca791b2b45e95c96871506babd2c553743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Community-Acquired Infections - blood</topic><topic>Community-Acquired Infections - complications</topic><topic>Emergency and intensive care: infection, septic shock</topic><topic>Female</topic><topic>HMGB1 Protein - blood</topic><topic>Humans</topic><topic>Immunoblotting</topic><topic>Immunomodulators</topic><topic>Intensive care medicine</topic><topic>Intensive Care Units</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumonia - blood</topic><topic>Pneumonia - complications</topic><topic>Pneumonia - physiopathology</topic><topic>Prospective Studies</topic><topic>Sepsis - blood</topic><topic>Sepsis - complications</topic><topic>Sepsis - physiopathology</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Angus, Derek C</creatorcontrib><creatorcontrib>Yang, LiHong</creatorcontrib><creatorcontrib>Kong, Lan</creatorcontrib><creatorcontrib>Kellum, John A</creatorcontrib><creatorcontrib>Delude, Russell L</creatorcontrib><creatorcontrib>Tracey, Kevin J</creatorcontrib><creatorcontrib>Weissfeld, Lisa</creatorcontrib><creatorcontrib>GenIMS Investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Angus, Derek C</au><au>Yang, LiHong</au><au>Kong, Lan</au><au>Kellum, John A</au><au>Delude, Russell L</au><au>Tracey, Kevin J</au><au>Weissfeld, Lisa</au><aucorp>GenIMS Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis</atitle><jtitle>Critical care medicine</jtitle><addtitle>Crit Care Med</addtitle><date>2007-04</date><risdate>2007</risdate><volume>35</volume><issue>4</issue><spage>1061</spage><epage>1067</epage><pages>1061-1067</pages><issn>0090-3493</issn><eissn>1530-0293</eissn><coden>CCMDC7</coden><abstract>OBJECTIVE:High-mobility group box 1 (HMGB1) has been proposed as a late mediator of sepsis, but human data are sparse and conflicting. We describe plasma HMGB1 concentrations in humans with community-acquired pneumonia (CAP), the most common cause of severe sepsis, and test the hypotheses that HMGB1 levels are higher in CAP than healthy controls, higher in CAP with severe sepsis than CAP without severe sepsis, and higher in severe sepsis nonsurvivors than survivors.
DESIGN:Random, outcome-stratified sample from a prospective study of 1,895 subjects hospitalized with CAP.
SETTING:Twenty-eight U.S. teaching and community hospitals.
PATIENTS:There were 122 CAP subjects (43 never developed severe sepsis, 49 developed severe sepsis and survived hospitalization, and 30 developed severe sepsis and died) and 38 healthy controls.
INTERVENTIONS:None.
MEASUREMENTS AND MAIN RESULTS:Median day of onset of severe sepsis was day of admission. HMGB1 was measured daily for the first week and analyzed using repeated-measures models with and without multivariable adjustment for baseline characteristics. HMGB1 concentrations were higher in CAP subjects compared with controls (median concentration on day of admission vs. controls, 190 vs. 0 ng/mL, p = .0001; 93.7% of all CAP measurements were elevated). HMGB1 remained elevated throughout the hospital course with no significant trend (p = .64) and did not differ between those with and without severe sepsis (p = .30). HMGB1 concentrations were higher in severe sepsis nonsurvivors than survivors (p = .001). HMGB1 concentrations remained elevated at discharge (median final HMGB1 measure, 176 ng/mL). Findings persisted in multivariable models and were robust to sensitivity analyses using alternative definitions of severe sepsis.
CONCLUSIONS:HMGB1 is elevated in almost all CAP subjects, and higher circulating HMGB1 is associated with mortality. But immunodetectable HMGB1 levels were also persistently elevated in those patients who fared well. Thus, additional work is needed to understand the biological activities of serum HMGB1 in sepsis.</abstract><cop>Hagerstown, MD</cop><pub>by the Society of Critical Care Medicine and Lippincott Williams & Wilkins</pub><pmid>17334246</pmid><doi>10.1097/01.CCM.0000259534.68873.2A</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0090-3493 |
ispartof | Critical care medicine, 2007-04, Vol.35 (4), p.1061-1067 |
issn | 0090-3493 1530-0293 |
language | eng |
recordid | cdi_proquest_miscellaneous_70363732 |
source | MEDLINE; Journals@Ovid Ovid Autoload |
subjects | Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Community-Acquired Infections - blood Community-Acquired Infections - complications Emergency and intensive care: infection, septic shock Female HMGB1 Protein - blood Humans Immunoblotting Immunomodulators Intensive care medicine Intensive Care Units Male Medical sciences Pharmacology. Drug treatments Pneumonia - blood Pneumonia - complications Pneumonia - physiopathology Prospective Studies Sepsis - blood Sepsis - complications Sepsis - physiopathology Severity of Illness Index |
title | Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T01%3A50%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20high-mobility%20group%20box%201%20(HMGB1)%20concentrations%20are%20elevated%20in%20both%20uncomplicated%20pneumonia%20and%20pneumonia%20with%20severe%20sepsis&rft.jtitle=Critical%20care%20medicine&rft.au=Angus,%20Derek%20C&rft.aucorp=GenIMS%20Investigators&rft.date=2007-04&rft.volume=35&rft.issue=4&rft.spage=1061&rft.epage=1067&rft.pages=1061-1067&rft.issn=0090-3493&rft.eissn=1530-0293&rft.coden=CCMDC7&rft_id=info:doi/10.1097/01.CCM.0000259534.68873.2A&rft_dat=%3Cproquest_cross%3E70363732%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70363732&rft_id=info:pmid/17334246&rfr_iscdi=true |